BioArctic & Biogen

BioArctic: BioArctic receives royalties from Leqembi sales; Q2 2026 royalty of SEK 179 million represents 10% growth, boosting revenue outlook.

Biogen: Biogen is a partner in Leqembi commercialization; the sales results contribute to its Q2 2026 report.

BioArctic: Inventor of lecanemab; entitled to royalties and sales milestones from Eisai. The US launch of Leqembi Iqlik strengthens its commercial prospects.

Biogen: Joint development and commercialization partner for lecanemab; benefits from increased sales.

BioArctic: As the inventor of Lecanemab and a partner in its development and commercialization, BioArctic stands to benefit significantly from the projected sales, receiving royalties and milestone payments. This event positively impacts its financial outlook.

Biogen: Biogen is a joint development and commercialization partner for Lecanemab, participating in clinical studies. While not the primary focus of this sales forecast, it benefits from the drug's success.

BioArctic: BioArctic, in collaboration with Eisai, developed Lecanemab and is set to receive approximately SEK 880 million in royalties from the projected sales, indicating a positive financial outlook for the company.

Biogen: Biogen entered into a joint development and commercialization agreement for lecanemab with Eisai in 2014 and is involved in the AHEAD 3-45 clinical study.

BioArctic: Greta Duréel has consulted for BioArctic, but no direct impact from this study.

Biogen: Greta Duréel has consulted for Biogen, but no direct impact from this study.